Open access
Open access
Powered by Google Translator Translator

Preventive Cardiology

AHA Statement | Optimizing prepregnancy cardiovascular health improves outcomes for pregnant women, offspring

15 Feb, 2023 | 16:14h | UTC

Summary: This statement highlights the need to optimize cardiovascular health before pregnancy to reduce the risk for adverse pregnancy outcomes and cardiovascular disease in mothers and children. It emphasizes the role of clinicians in promoting early cardiovascular health, clinical trials to investigate interventions, and the use of a life course framework to monitor health. By targeting cardiovascular health before pregnancy, interventions can improve health outcomes across generations.*

Article: Optimizing Prepregnancy Cardiovascular Health to Improve Outcomes in Pregnant and Postpartum Individuals and Offspring: A Scientific Statement From the American Heart Association – Circulation

News Release: Does risk for heart disease start before birth? – American Heart Association

 

*Note: This summary was created through the collaboration of a medical editor and ChatGPT.

 

Updated Guideline | Cardiovascular disease risk assessment and reduction, including lipid modification

13 Feb, 2023 | 12:47h | UTC

Cardiovascular disease: risk assessment and reduction, including lipid modification – National Institute for Health and Care Excellence

Related Guidelines:

USPSTF Recommendation Statement | Statin use for the primary prevention of cardiovascular disease in adults.

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease – Circulation

#ESCCongress – 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

#ESCCongress – 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology – 2019 – Arquivos Brasileiros de Cardiologia

Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update – Canadian Medical Association Journal

 

Abbreviated lipid guidelines for clinical practice

13 Feb, 2023 | 12:46h | UTC

Abbreviated lipid guidelines for clinical practice : Based on ESC lipid guidelines 2019 and ESC cardiovascular disease prevention in clinical practice guidelines 2021 – Irish Journal of Medical Science

Original Guidelines

#ESCCongress – 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

#ESCCongress – 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

Related:

Cardiovascular disease: risk assessment and reduction, including lipid modification – National Institute for Health and Care Excellence

USPSTF Recommendation Statement | Statin use for the primary prevention of cardiovascular disease in adults.

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease – Circulation

Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology – 2019 – Arquivos Brasileiros de Cardiologia

Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update – Canadian Medical Association Journal

 

Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts

8 Feb, 2023 | 12:14h | UTC

Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts – The Lancet (link to abstract – $ for full-text)

News Release: Digital marker for coronary artery disease built by researchers at Mount Sinai

Commentary: Machine learning used to generate a new holistic model for coronary artery disease – News Medical

 

Commentary from the author on Twitter (thread – click for more)

 

M-A | Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and CKD

1 Feb, 2023 | 13:06h | UTC

Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis – Pharmacology

 

WHO | Five billion people unprotected from trans-fat leading to heart disease

24 Jan, 2023 | 14:44h | UTC

News Release: Five billion people unprotected from trans fat leading to heart disease – World Health Organization

Report: Countdown to 2023: WHO report on global trans-fat elimination 2022 – World Health Organization

Commentary: Five Billion People Exposed to Industrially Produced Trans Fats – Health Policy Watch

Related:

Brazil and Peru join growing number of countries in the Americas that are eliminating industrially produced trans fats – Pan American Health Association / World Health Organization

WHO: More than 3 billion people protected from harmful trans-fat in their food

Action Package: WHO Plan to Eliminate Trans-fatty Acids from Global Food Supply

WHO Draft Guideline: Saturated Fatty Acid and Trans-fatty Intake for Adults and Children

Banning trans fats in New York prevented thousands of heart attacks

 

Review | Cardiovascular outcomes in type 1 and type 2 diabetes

23 Jan, 2023 | 13:18h | UTC

Cardiovascular outcomes in type 1 and type 2 diabetes – Diabetologia

 

Commentary on Twitter

Article under a http://creativecommons.org/licenses/by/4.0/. License

 

M-A | Prospective association of daily steps with cardiovascular disease

10 Jan, 2023 | 14:29h | UTC

Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis – Circulation (link to abstract – $ for full-text)

Commentaries: 

CVD Benefits of Activity Seen Below Widely Quoted Step Goal in Older Adults – TCTMD

Heart health tip for older adults in 2023: Step it up a bit – University of Massachusetts Amherst

 

Commentary on Twitter

 

RCT | Chlorthalidone (12.5-25 mg) and Hydrochlorothiazide (25-50 mg) are similarly effective for the prevention of CVD in hypertensive patients.

16 Dec, 2022 | 13:49h | UTC

Chlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: ‘Burden-free’ study method finds two blood pressure drugs equally effective – Veterans Affairs Research Communications

Related (news release and commentaries before publication): RCT | Chlortalidone and Hydrochlorothiazide resulted in similar reductions of CVD in older patients with hypertension.

 

Commentary on Twitter

 

Cohort Study | Association of the triglyceride glucose index as a measure of insulin resistance with mortality and CVD

9 Jan, 2023 | 13:42h | UTC

Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study – The Lancet Health Longevity

Invited Commentary: The triglyceride glucose index and cardiovascular disease outcomes – The Lancet Health Longevity

 

Cohort Study | Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood.

9 Dec, 2022 | 13:11h | UTC

Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood – Circulation

Commentary: Lp(a) in Youth and Risk of ASCVD Outcomes in Adulthood – American College of Cardiology

 

Commentary on Twitter

 

Cohort Study | Adding salt to foods linked to increased risk of cardiovascular disease.

6 Dec, 2022 | 14:04h | UTC

Adding Salt to Foods and Risk of Cardiovascular Disease – Journal of the American College of Cardiology (link to abstract – $ for full-text)

News Release: Shaking less salt on your food at the table could reduce heart disease risk – American College of Cardiology

Commentaries:

Adding Salt to Food and Risk of Cardiovascular Disease – American College of Cardiology

Lower Frequency of Adding Salt to Food Linked to Lower CVD Risk – HealthDay

 

M-A | Cardioprotective effects of influenza vaccination in patients with high risk of cardiovascular disease.

25 Nov, 2022 | 12:47h | UTC

Cardioprotective effects of influenza vaccination among patients with established cardiovascular disease or at high cardiovascular risk: a systematic review and meta-analysis – European Journal of Preventive Cardiology (free for a limited period)

Related:

RCT | Influenza vaccine to reduce adverse vascular events in patients with heart failure.

RCT | A double-dose influenza vaccination during hospitalization for acute coronary syndrome did not improve outcomes compared to standard-dose outpatient vaccination.

 

Cohort Study | Race-dependent association of HDL-C levels with incident coronary artery disease.

23 Nov, 2022 | 14:02h | UTC

Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease – Journal of the American College of Cardiology

Editorial: HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity? – Journal of the American College of Cardiology

News Release: Study challenges “good” cholesterol’s role in universally predicting heart disease risk – National Institutes of Health

Commentary: Study suggests that HDL or ‘good’ cholesterol is less beneficial than previously thought, especially for Black adults – CNN

 

Cohort Study | Polygenic risk score improves the accuracy of a clinical risk score for coronary artery disease.

23 Nov, 2022 | 13:55h | UTC

Polygenic risk score improves the accuracy of a clinical risk score for coronary artery disease – BMC Medicine

Related:

AHA Scientific Statement | Polygenic risk scores for cardiovascular disease.

Incremental Value of Polygenic Risk Scores in Primary Prevention of Coronary Heart Disease: A Review – JAMA Internal Medicine

Cohort Study | Predictive utility of a validated polygenic risk score for long-term risk of coronary heart disease in young and middle-aged adults.

Cohort Study | Polygenic risk, midlife life’s simple 7, and lifetime risk of stroke.

Cohort Study: A polygenic risk score may improve risk stratification of coronary artery disease.

Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.

Studies: Little Benefit from Polygenic Risk Score vs. Clinical Risk Score for Predicting Cardiovascular Risk

 

Commentary on Twitter

 

RCT | Comparative effects of low-dose rosuvastatin vs. dietary supplements on lipids and inflammatory biomarkers.

16 Nov, 2022 | 13:41h | UTC

Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers – Journal of the American College of Cardiology

News Release: 6 common “heart-health” supplements ineffective at lowering cholesterol compared to statins – American Heart Association

Commentaries: 

Study – For Lowering Cholesterol, Statins Work, Supplements Don’t – Science-Based Medicine

Statins vs. supplements: New study finds one is ‘vastly superior’ to cut cholesterol – NPR

 

Cohort Study | Childhood adversity and cardiovascular disease in early adulthood.

16 Nov, 2022 | 13:29h | UTC

Childhood adversity and cardiovascular disease in early adulthood: a Danish cohort study – European Heart Journal (free for a limited period)

Commentary: Study explores the links between childhood adversity and cardiovascular disease in early adulthood – European Society of Cardiology/News Medical

 

Commentary from the author on Twitter

https://twitter.com/HulvejRod/status/1592520830155886593

 

Canadian guideline for the prevention and management of cardiovascular disease in primary care.

8 Nov, 2022 | 12:37h | UTC

Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update – Canadian Medical Association Journal

News Release: New one-stop guideline for cardiovascular health in Canada – Canadian Medical Association Journal

 

RCT | Triglyceride lowering with Pemafibrate fails to reduce CVD risk in patients with Type 2 DM and hypertriglyceridemia.

7 Nov, 2022 | 12:54h | UTC

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk – New England Journal of Medicine (link to abstract – $ for full-text)

News Releases:

New medicine reduces triglyceride by 25%, no change in CVD risk in people with Type 2 diabetes – American Heart Association

Triglyceride-lowering trial neutral for cardiovascular event reduction – Brigham and Women’s Hospital

Commentaries:

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT – TCTMD

PROMINENT: Pemafibrate Effective in Lowering Tryglycerides, But Not Reducing Risk of CV Events – American College of Cardiology

 

Commentary on Twitter

 

Cohort Study | Pre-eclampsia is associated with increased risk of premature-onset obstructive coronary artery stenosis.

1 Nov, 2022 | 12:02h | UTC

Severity of obstructive coronary artery stenosis after pre-eclampsia – Heart

Related:

Primary Care–Based Cardiovascular Disease Risk Management After Adverse Pregnancy Outcomes: a Narrative Review – Journal of General Internal Medicine

Pregnancy Complications and Risk of Cardiovascular Disease Later in Life: A Nationwide Cohort Study – Journal of the American Heart Association

AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk

Consensus statement: Cardiovascular health after menopause transition, pregnancy disorders, and other gynecologic conditions

Cohort Study: Preeclampsia and Cardiovascular Disease

Cohort Study: Cardiovascular Disease After Hypertensive Disorders of Pregnancy Largely Explained by Conventional Cardiovascular Risk Factors

All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease

Gestational Hypertension and Future Risk of Cardiovascular Disease

Research: Conjoint Associations of Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular Disease in Parents

 

M-A | Age, sex, race, BMI, and duration of type 2 DM differences in cardiovascular outcomes with glucose lowering drugs.

26 Oct, 2022 | 14:32h | UTC

Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis – eClinicalMedicine

Commentary: Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection – medwire News

 

Cohort Study | Associations of hypertriglyceridemia onset age with cardiovascular disease and all‐cause mortality in adults.

20 Oct, 2022 | 12:25h | UTC

Associations of Hypertriglyceridemia Onset Age With Cardiovascular Disease and All‐Cause Mortality in Adults: A Cohort Study – Journal of the American Heart Association

 

RCT | Combination of pitavastatin and ezetimibe vs. monotherapy of pitavastatin in patients with primary hypercholesterolemia.

19 Oct, 2022 | 14:15h | UTC

A Multicenter, Randomized, Double-Blind, Active-Controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia – Clinical Therapeutics

 

Retrospective Cohort Study | Trends in the association between diabetes and cardiovascular events, 1994-2019.

18 Oct, 2022 | 12:58h | UTC

Trends in the Association Between Diabetes and Cardiovascular Events, 1994-2019 – JAMA (free for a limited period)

Related Study: Study shows that the leading causes of hospitalization of adults with diabetes are changing.

 

Perspective | The polypill: from concept and evidence to implementation.

18 Oct, 2022 | 12:55h | UTC

The polypill: from concept and evidence to implementation – The Lancet (free registration required)

News Release: The polypill could avoid millions of premature deaths, heart attacks and strokes every year, say leading cardiology experts – McMaster University

Related:

#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.

#ESCCongress – M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention.

Opinion: A new important study supports wider use of the polypill

#AHA20 – Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk

Perspective: Are Polypills and Population-based Treatment the Next Big Things?

The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era

Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population

Randomized Trial: Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases

Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology – Global Heart

Perspective: The Polypill and the Long Journey to Major Impact

Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.